A study of model beta-cells in Diabetes Treatment
模型β细胞在糖尿病治疗中的研究
基本信息
- 批准号:8003246
- 负责人:
- 金额:$ 6.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-01-11 至 2011-01-11
- 项目状态:已结题
- 来源:
- 关键词:AddressAlginatesAnatomyBeta CellBioenergeticsCell DensityCell NucleusCellsCharacteristicsCoupledDataDiabetes MellitusEncapsulatedEventFailureGlucoseGrowthHypoxiaImageImaging TechniquesImplantIn VitroMetabolicMetabolismMethodologyModalityModelingMonitorMusOxygenPancreasPhysiologicalPhysiologyRF coilResearchResearch DesignRetrievalRoleSepharoseSignal TransductionSiteStimulusStructureStudy modelsTechniquesTetanus Helper PeptideTimeTissue EngineeringTreatment Efficacybasecell fixationdesignextracellularimplantationin vivoindexinginsulin secretioninsulinomaisletpoly-L-lysine alginateresearch studyrestorationspectroscopic imaging
项目摘要
DESCRIPTION (provided by applicant): The main criterion in assessing the therapeutic efficacy of tissue engineered construct is the successful restoration of the host's physiology. Direct and non-invasive in vivo monitoring of a construct is of great importance for the following reasons: it provides correlations between construct function and physiologic effects post-implantation in vivo; and it offers the possibility of assessing changes in construct function that may be used to develop early markers of construct failure in advance of the end-point effects. The overall objective of the proposed research is to develop a noninvasive methodology to monitor in vivo the function of an implanted tissue engineered pancreatic substitute. NMR is uniquely suited to perform such studies since it is a non-invasive modality that has the ability to probe into the intracellular metabolism of the construct, and to view the anatomy of the host at the site of implantation. NMR spectroscopic and imaging techniques can monitor several intracellular and extracellular metabolites without necessitating the introduction of foreign agents or the fixation of cells. It is our hypothesis that NMR detectable metabolic indexes can be used to monitor the function of an implanted tissue engineered pancreatic substitute and provide early indicators of implant failure while the recipient is still euglycemic. The NMR nuclei examined in this study include 1H, 19F and 31P, while the model pancreatic construct utilized is composed of mouse insulinoma #TC-tet cells or mouse islets encapsulated in alginate/poly-L- lysine/alginate beads and contained within an agarose matrix that allows for easy retrieval. The following Specific Aims are designed to address our hypothesis: Specific Aim 1: To optimize in vivo NMR signal acquisition with inductively coupled RF-coils. Specific Aim 2: To develop and validate a model of time-dependent oxygen and cell density gradients within constructs. Specific Aim 3: To non-invasively assess the function of an implanted tissue engineered pancreatic substitute and correlate that to end point physiologic events. We believe this to be a thorough, quantitative and a significant study to monitor the function of an implanted tissue engineered substitute that will identify metabolic events associated with failure ahead of its end physiologic effect. Proposed experiments are founded on strong preliminary data and we are confident that they will pave the way for further imaging studies in tissue engineering.
描述(申请人提供):评估组织工程构建体治疗效果的主要标准是宿主生理机能的成功恢复。对构建体进行直接和非侵入性的体内监测非常重要,原因如下:它提供了构建体功能和体内植入后生理效应之间的相关性;它提供了评估构建功能变化的可能性,可用于在终点效应之前开发构建失败的早期标记。拟议研究的总体目标是开发一种非侵入性方法来监测植入的组织工程胰腺替代物的体内功能。 NMR 特别适合进行此类研究,因为它是一种非侵入性方式,能够探测构建体的细胞内代谢,并查看植入部位宿主的解剖结构。核磁共振波谱和成像技术可以监测多种细胞内和细胞外代谢物,无需引入外源试剂或固定细胞。我们的假设是,核磁共振可检测的代谢指标可用于监测植入的组织工程胰腺替代物的功能,并在受体血糖仍正常时提供植入失败的早期指标。本研究中检查的 NMR 核包括 1H、19F 和 31P,而使用的模型胰腺构建体由小鼠胰岛素瘤 #TC-tet 细胞或小鼠胰岛组成,封装在海藻酸盐/聚-L-赖氨酸/海藻酸盐珠中,并包含在易于检索的琼脂糖基质中。以下具体目标旨在解决我们的假设: 具体目标 1:利用电感耦合射频线圈优化体内 NMR 信号采集。具体目标 2:开发并验证构建体内随时间变化的氧气和细胞密度梯度模型。具体目标 3:非侵入性评估植入的组织工程胰腺替代物的功能,并将其与终点生理事件相关联。我们相信这是一项彻底、定量且重要的研究,旨在监测植入的组织工程替代品的功能,该替代品将在其最终生理效应之前识别与失败相关的代谢事件。拟议的实验建立在强有力的初步数据的基础上,我们相信它们将为组织工程的进一步成像研究铺平道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NICHOLAS E SIMPSON其他文献
NICHOLAS E SIMPSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NICHOLAS E SIMPSON', 18)}}的其他基金
BIOENERGETIC REQUIREMENTS FOR A BIOARTIFICIAL PANCREAS
生物人工胰腺的生物能要求
- 批准号:
6214005 - 财政年份:2000
- 资助金额:
$ 6.29万 - 项目类别:
BIOENERGETIC REQUIREMENTS FOR A BIOARTIFICIAL PANCREAS
生物人工胰腺的生物能要求
- 批准号:
2862811 - 财政年份:1999
- 资助金额:
$ 6.29万 - 项目类别:
A study of model beta-cells in Diabetes Treatment
模型β细胞在糖尿病治疗中的研究
- 批准号:
7673995 - 财政年份:1995
- 资助金额:
$ 6.29万 - 项目类别:
A study of model beta-cells in Diabetes Treatment
模型β细胞在糖尿病治疗中的研究
- 批准号:
7278167 - 财政年份:1995
- 资助金额:
$ 6.29万 - 项目类别:
A study of model beta-cells in Diabetes Treatment
模型β细胞在糖尿病治疗中的研究
- 批准号:
7901500 - 财政年份:1995
- 资助金额:
$ 6.29万 - 项目类别:
A study of model beta-cells in Diabetes Treatment
模型β细胞在糖尿病治疗中的研究
- 批准号:
7492255 - 财政年份:1995
- 资助金额:
$ 6.29万 - 项目类别:
相似海外基金
Étude des interactions de sorption et de séquestration de polluants sur des alginates
海藻酸盐污染物吸附与封存相互作用研究
- 批准号:
571945-2022 - 财政年份:2022
- 资助金额:
$ 6.29万 - 项目类别:
University Undergraduate Student Research Awards
Engineering an Islet Thread from zwitterionically modified alginates for type 1 diabetes
利用两性离子改性藻酸盐设计胰岛丝,用于治疗 1 型糖尿病
- 批准号:
9910390 - 财政年份:2018
- 资助金额:
$ 6.29万 - 项目类别:
Engineering an Islet Thread from zwitterionically modified alginates for type 1 diabetes
利用两性离子改性藻酸盐设计胰岛丝,用于治疗 1 型糖尿病
- 批准号:
10402773 - 财政年份:2018
- 资助金额:
$ 6.29万 - 项目类别:
ALGIPRO - Alginates by Production Scale Fermentation and Epimerisation
ALGIPRO - 通过生产规模发酵和差向异构化生产海藻酸盐
- 批准号:
102148 - 财政年份:2016
- 资助金额:
$ 6.29万 - 项目类别:
Collaborative R&D